Clinical Trial Update: Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating anlotinib plus etoposide and carboplatin as first-line therapy for extensive-stage small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: SCLC, Anlotinib | Phase 2 | Status: UNKNOWN